Preliminary Evaluation of Influence of Different Targeted Drugs of Vascular Endothelial Growth Factor Signaling Pathway on the Proliferation of Neuroendocrine Neoplasm Cell Lines Abstract #2008
Introduction: Sunitinib and bevacizumab are intracellular and extracellular inhibitor of vascular endothelial growth factor(VEGF) pathway respectively, the influence of both of which on the proliferation of neuroendocrine neoplasm (NEN) cell lines in vitro was not known yet.
Aim(s): To evaluate the influence of sunitinib and bevacizumab on the proliferation of neuroendocrine neoplasm cell lines in vitro.
Materials and methods: Human bronchial carcinoid cell line NCI-H727 and pancreatic neuroendocrine neoplasm cell line QGP-1 were treated with sunitinib and bevacizumab of different concentrations, cell proliferation and VEGF signaling were detected.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Professor Jie Chen
To read results and conclusion, please login ...
Further abstracts you may be interested in
#62 Genome-wide DNA methylation profiling of pancreatic neuroendocrine tumors identifies distinct methylation profiles and differentially methylated gene promoter regions associated with low, medium and high grade tumors
Introduction: Integration of genetics and epigenetics has emerged as a powerful approach to studying cellular differentiation (Mikkelsen et al, 2009) and tumorigenesis (Shen et al, 2007). The study of DNA methylation is of particular importance in cancer, as causal involvement has been demonstrated and it is the most stable of all epigenetic modifications, making it a desirable marker for both early detection and treatment of tumors. Hypermethylation of CpG sites in gene promoter regions leads to decreased gene expression; if such a gene is a tumor suppressor, this leads to carcinogenesis. To date, there have been no studies of genome-wide DNA methylation profiling of NETs. This study sets out to determine the DNA methylation profiles of low, intermediate and high grade pancreatic NET liver metastases with the intention of identifying dysregulated biological pathways in the development of these tumors. A protocol for the analysis formalin-fixed paraffin embedded tissue (FFPE) has also been developed in order to study these tumors in significant numbers following this pilot study.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: Dr Christina Thirlwell
Keywords: DNA methylation, CpG dinucleotides, genome-wide, differentially methylated region (DMR) References: Duerr EM et al Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer. 2008 Mar;15(1):243-56 Kulke MH et al O6 –methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumours. Clin Cancer Res 2009; 15(1): 338-345 Mikkelsen TS et al Dissecting direct reprogramming through integrative genomic analysis. Nature. 2008 454(7200):49-55. Shen L et al Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9.
#823 Association Between Tumor Expression of VEGFA, VEGFR1 (FLT1), VEGFR2 (KDR), and Clinical Outcomes in Neuroendocrine Tumors
Introduction: Clinical studies have suggested efficacy of VEGF pathway inhibitors in the treatment of advanced neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. Zhirong Qian
#912 Serial 89Zr-bevacizumab PET in Patients with Neuroendocrine Tumors before and on Everolimus Treatment
Introduction: Everolimus increases PFS in patients with advanced NETs. Currently, no biomarkers are available for early selection of patients who will benefit from everolimus. Everolimus can reduce VEGF-A production by tumor cells.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Adrienne H Brouwers
#1171 Clinical Characteristics and Treatment Outcome of Six Advanced G3 Well-Differentiated Neuroendocrine Tumors
Introduction: According to 2010 WHO grading system, all neuroendocrine neoplasms were divided into G1/G2/G3 based on Ki-67 and mitotic count. However, differentiation was also very important for the biological behavior and treatment strategy.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Ru Jia
#1334 Early Evaluation of Sunitinib in Treatment of Advanced Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) by CT Imaging: RECIST or Choi Criteria?
Introduction: There is no study to assess RECIST and Choi criteria in evaluating response of advanced GEP-NENs treated with sunitinb.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Yanji Luo